TP53 and hepatocellular carcinoma: Despite the recent advances in HCC therapy, precision medicine has not yet found clinical application and HCC cases are treated similarly, since the most common driver gene mutations in this disease (TERT promoter, CTNNB1, TP53, and ARID1 mutations) have not yet been translated into effective therapeutic targets (10).